The 7 analysts offering 12-month price forecasts for Royalty Pharma PLC have a median target of 50.00, with a high estimate of 56.00 and a low estimate of 46.00. The median estimate represents a +27.70% increase from the last price of 39.16.
The current consensus among 7 polled investment analysts is to Buy stock in Royalty Pharma PLC. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.77
Reporting Date Feb 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.